New hope for catheter patients: expanded access to Infection-Fighting drug DefenCath
NCT ID NCT06707480
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This expanded access program offers DefenCath, a catheter lock solution containing taurolidine and heparin, to adult and pediatric patients who need a catheter but cannot join ongoing clinical trials or do not meet the current FDA-approved label. The goal is to prevent central line-associated bloodstream infections (CLABSIs) in these patients. The program is available now and aims to provide broader access to this preventive treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DefenCath (taurolidine and heparin catheter lock solution)
- What this could lead to
- If successful, this program could help prevent serious bloodstream infections in patients who need catheters but cannot join clinical trials or use the approved treatment.
- What could go wrong
- This is an expanded access program, not a formal trial, so data on safety and effectiveness is limited. Results may not apply to all patients, and risks like bleeding or allergic reactions remain possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CATHETER-RELATED BLOODSTREAM INFECTION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.